| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Oct 2025 - 31 Mar 2026 | 27 Apr 2026 | 56 | 38% | 31% | 31% | 14% |
| 01 Apr 2025 - 30 Sept 2025 | 06 Nov 2025 | 54 | 39% | 32% | 29% | 18% |
| 01 Oct 2024 - 31 Mar 2025 | 30 Apr 2025 | 54 | 40% | 29% | 31% | 5% |
| 01 Apr 2024 - 30 Sept 2024 | 29 Oct 2024 | 53 | 32% | 38% | 30% | 20% |
| 01 Oct 2023 - 31 Mar 2024 | 24 Apr 2024 | 63 | 29% | 33% | 38% | 29% |
| 01 Apr 2023 - 30 Sept 2023 | 19 Oct 2023 | 54 | 33% | 32% | 35% | 28% |
| 01 Oct 2022 - 31 Mar 2023 | 28 Apr 2023 | 56 | 39% | 28% | 33% | 27% |
| 01 Apr 2022 - 30 Sept 2022 | 31 Oct 2022 | 48 | 39% | 31% | 30% | 26% |
| 01 Oct 2021 - 31 Mar 2022 | 27 Apr 2022 | 56 | 34% | 28% | 37% | 33% |
| 01 Apr 2021 - 30 Sept 2021 | 26 Oct 2021 | 48 | 40% | 28% | 31% | 19% |
| 01 Oct 2020 - 31 Mar 2021 | 28 Apr 2021 | 47 | 43% | 29% | 28% | 19% |
| 01 Apr 2020 - 30 Sept 2020 | 26 Oct 2020 | 50 | 39% | 27% | 34% | 20% |
| 01 Jul 2019 - 31 Mar 2020 | 31 Jul 2020 | 46 | 40% | 31% | 29% | 22% |
| 01 Jul 2018 - 31 Dec 2018 | 22 Jan 2019 | 45 | 40% | 34% | 26% | 17% |
| 01 Jan 2018 - 30 Jun 2018 | 27 Jul 2018 | 52 | 27% | 24% | 49% | 43% |
This information is as reported by the business, and responses are in their own words.
Standard payment terms
It is the company’s policy to agree appropriate terms of payment with suppliers for each transaction or series of transactions, and to abide by those terms based on the timely submission of satisfactory invoices. The company normally seeks to settle trade payables on 75 days terms, however variations to these terms do exist based upon agreements with certain suppliers. The company is amenable to agreeing discounted payment terms with suppliers where to do so would be mutually beneficial.
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
N/A
Maximum contractual payment period agreed
90
The company is committed to dealing with its suppliers in a fair, honest and professional manner. We seek to resolve queries as quickly as possible. We have a dedicated accounts payable team that offers suppliers support through to query resolution. The team can be contacted from Monday through to Friday by email (EP-purchaseledger.ukrun@Epredia.com). Contact by e-mail is typically acknowledged same-day, but always within 24 hours. The accounts payable team will work to resolve queries in the first instance, with escalation to the internal purchasing team if required. Any query that cannot be resolved at this stage would then be escalated to the relevant head of department to seek a resolution.
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Shandon Diagnostics Limited is a UK registered company, incorporated in 1937, that forms part of the Thermo Fisher Scientific group. Its registered business classification covers the manufacture of medical and dental instruments and supplies. The wider Thermo Fisher Scientific group, of which this entity is a part, provides scientific instruments, laboratory equipment, reagents, diagnostics and related services to biotech, pharmaceutical, clinical and research customers worldwide. No specific operational detail about this individual entity's own activities, beyond its registration and group membership, is available in the evidence provided.
Generated from the company's website and Companies House records. Sources: thermofisher.com